Introduction
iCAD, Inc., a global leader in AI-powered cancer detection solutions, is set to showcase groundbreaking research at the Society for Imaging Informatics in Medicine (SIIM) Annual Meeting 2024. The focus will be on the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment and the recently launched ProFound Cloud platform. These innovations promise to revolutionize breast cancer detection and risk assessment, offering medical providers cost-effective, secure, and scalable AI solutions.
ProFound AI Risk Algorithm
Overview
The ProFound AI Risk algorithm by iCAD is designed to provide a more accurate assessment of breast cancer risk than traditional models. This AI-driven tool analyzes mammographic features, density, and age to predict a woman’s one-year absolute risk of developing breast cancer. The algorithm’s ability to detect subtle changes in mammographic images over time makes it a valuable asset in early breast cancer detection and personalized risk assessment.
Research Presentation by Dr. Mark Traill
Dr. Mark Traill, a prominent breast radiologist from the University of Michigan Health-West, will present his research titled “The Change in Image-Derived AI-Based Risk Scores to Identify Women at an Increased Likelihood of Breast Cancer.” This presentation, scheduled for June 27 at 4:15 pm ET, will explore how changes in AI-derived risk scores between a woman’s prior and current mammograms can effectively predict breast cancer risk.
ProFound Cloud Platform
Overview
The ProFound Cloud platform is an advanced software-as-a-service (SaaS) solution built on the Google Cloud Platform (GCP). It provides medical providers seamless access to iCAD’s ProFound Breast Health Suite of AI solutions. This platform is designed to enhance diagnostic accuracy, operational efficiency, and patient outcomes by integrating cutting-edge AI technology into medical practices.
Key Features
ProFound Cloud offers several advanced capabilities, including continuous updates, scalability, and secure data handling. It allows healthcare providers to deploy AI solutions rapidly without extensive on-premises infrastructure, reducing the total cost of ownership. This flexibility ensures that healthcare facilities of all sizes can benefit from the latest advancements in breast health AI technology.
Clinical Abstract Highlights
Study Design and Results
Dr. Traill’s study investigates the use of AI-derived risk scores from prior and current mammograms to calculate breast cancer risk. The retrospective study involved 514 control participants and 52 cancer cases, analyzing changes in risk scores over time. The findings indicate that a change in AI-derived risk score between mammograms is a strong predictor of breast cancer risk, with a two-fold increase in risk for every 0.2 unit increase in the score.
Implications for Breast Cancer Risk Assessment
The study’s results highlight the potential of AI-driven risk assessment in identifying women at higher risk of breast cancer. By analyzing changes in risk scores, healthcare providers can facilitate earlier intervention and improve patient outcomes. The ability to offer personalized screening and ongoing surveillance based on AI-derived risk scores represents a significant advancement in breast cancer detection and prevention.
Conclusion
iCAD’s presentation at SIIM 2024 underscores the transformative potential of AI in breast cancer risk assessment and detection. The ProFound AI Risk algorithm and ProFound Cloud platform are set to provide healthcare providers with powerful tools to enhance diagnostic accuracy, operational efficiency, and patient care. Attendees of SIIM 2024 are encouraged to visit iCAD’s booth to learn more about these innovations and their impact on breast health.
Discover the latest Provider news updates with a single click. Follow DistilINFO HospitalIT and stay ahead with updates. Join our community today!
FAQs
Q1: What is the ProFound AI Risk algorithm?
A1: The ProFound AI Risk algorithm is an AI-driven tool designed to assess a woman’s one-year absolute risk of developing breast cancer by analyzing mammographic features, density, and age.
Q2: How does the ProFound Cloud platform benefit healthcare providers?
A2: The ProFound Cloud platform provides cost-effective, secure, and scalable access to iCAD’s AI solutions, enhancing diagnostic accuracy and operational efficiency without the need for extensive on-premises infrastructure.
Q3: What were the key findings of Dr. Traill’s study?
A3: Dr. Traill’s study found that changes in AI-derived risk scores between mammograms are strong predictors of breast cancer risk, with significant implications for early detection and personalized screening.
Q4: When and where will Dr. Traill present his research?
A4: Dr. Traill will present his research at the SIIM Annual Meeting 2024 on June 27 at 4:15 pm ET.
Q5: How can attendees learn more about iCAD’s AI solutions at SIIM 2024?
A5: Attendees can visit iCAD’s booth #413 at SIIM 2024 to learn more about the ProFound Cloud platform and the ProFound Breast Health Suite of AI solutions.
